Intravenous Revatio approved for pulmonary arterial hypertension (PAH)

The FDA has approved Revatio (sildenafil, from Pfizer) injection, an intravenous phosphodiesterase-5 (PDE-5) inhibitor, for the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening. Revatio injection is for the continued treatment of patients with PAH who are currently prescribed Revatio tablets but who are temporarily unable to take oral medication.

Revatio injection will be available in early 2010 in a single-use vial. Revatio tablets are already available in a 20mg dosage strength.

For more information call (800) 438-1985 or visit www.revatio.com.